FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer

FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival